Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × dupilumab × Breast × Clear all
NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Recruiting
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05967884 2023-08-01

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Ottawa Hospital Research Institute

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡